Clinical Trials
Therapeutics company announces that phase I trial of CS-917 is continuing
Published in Cancer Weekly, April 26th, 2005
Metabasis Therapeutics, Inc., (MBRX) announced that while it is continuing to work with its partner Sankyo, investigators and other experts to fully evaluate the implications of the serious adverse events, the company has been informed that a phase I clinical trial of CS-917 is continuing and that one or more additional phase I clinical trials may be initiated soon to further evaluate the product candidate.
In parallel with this activity, Metabasis and Sankyo, together and separately, are evaluating what, if any, next steps should be taken in the CS-917 program.
"While the recent findings in the CS-917 development program are unfortunate and the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-04-26)
More Articles from Cancer Weekly
- Cancer Therapy
Transcription factor 3 contributed to curcumin's proapoptotic effect - Carcinogenesis
Carcinogenicity of acrylamide explored - Cervical Cancer
Estrogen plays etiological role in HPV-transgenic mouse model - Follicular Thyroid Cancer
Expression profiling revealed transcription signature in thyroid carcinomas - Leukemia Vaccine
Multidrug resistance of leukemia cells decreases tumorigenicity - Acute Leukemia
ALL and AML have distinct methylation profiles - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
